| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD3 receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| (verify) | |
Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]
PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009[update].
Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]
- ^ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11.
- ^ "PDL Lands in a Hazard". 29 August 2007. Retrieved 2009-05-27.
- ^ Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov
- ^ Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/Metabolism Research and Reviews. 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985. S2CID 36595661.
- ^ Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov
- ^ Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, et al. (October 2009). "Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes" (PDF). Journal of Nuclear Medicine. 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100. S2CID 31980716.